BioLum Sciences specializes in bioanalytical chemistry for reactive oxygen and nitrogen species (RONS) centered around our core analysis platform and chemiluminescent assays. BioLum's technology measures biomarkers in exhaled breath condensate and blood samples, empowering pharmaceutical researchers and clinicians with tools to develop and personalize treatments for patients with chronic diseases such as asthma, chronic obstructive pulmonary disease (COPD), hypertension, and heart failure. BioLum also offers R&D services in assay development, compound analysis, and specific analyte measurements, with an emphasis on oxidative stress and nitric oxide signaling. With the advent of biomarker analysis for monitoring disease severity and progression, there is a desire to shift towards remote patient monitoring via non-invasive biomarkers to improve treatment plans and lower overall costs on the healthcare system. Our initial programs are focused on asthma, COPD, and heart disease. Our breath analysis product, The BioSense AMD (Airway Monitoring Device), provides a ‘window into the lung’ by measuring oxidative stress markers in exhaled breath condensate (EBC). Our test requires no complicated breathing maneuvers, allowing reliable at-home monitoring. These frequent, objective measurements of lung function offer significant patient benefits, provide physicians a tool to optimize treatment, and enable researchers to stratify patients in clinical trials to better understand chronic respiratory disease states. Our blood analysis product measures nitric oxide and nitrative stress metabolites in the blood using a finger-prick test. This point-of-care test will provide physicians, researchers, and patients with a critical gauge of endothelial dysfunction and cardiovascular health.